ACTRN12605000393651
Not yet recruiting
Phase 1
The Pharmacogenetic and Pathological Assessment of CYP2C19 Activity in Patients with Advanced Cancer as determined by omeprazole metabolism
Cancer Trials New Zealand0 sites50 target enrollmentSeptember 14, 2005
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Advanced cancer
- Sponsor
- Cancer Trials New Zealand
- Enrollment
- 50
- Status
- Not yet recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with advanced cancer who last received cytotoxic or hormonal therapy for their cancer more than four weeks ago and who are being considered for a new line of therapy for disease progression or inadequate response to prior therapy; adequate renal and liver function; Patients must be able to provide informed consent
Exclusion Criteria
- •Patients receiving medication which is either a CYP2C19 inhibitor or inducer.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Clinical pharmacology and pharmacogenetic study on the clinical response for tamoxifeBreast cancerJPRN-UMIN000001411Saitama Medical University, Saitama International Medical Center100
Active, not recruiting
Not Applicable
Aspects Pharmacogénétiques et Pharmacocinétiques de la réponse à la CHimiothérapie d’induction par Docetaxel, Cisplatine et 5-Fluorouracile (TPF), des cancers OREUCTR2008-006874-14-FRCHU de Nîmes
Completed
Phase 1
Efficacy and safety of Chinese herbal medicine (RCM-102) for treatment of seasonal allergic rhinitis (hayfever)seasonal allergic rhinitisInflammatory and Immune System - AllergiesRespiratory - Other respiratory disorders / diseasesAlternative and Complementary Medicine - Herbal remediesACTRN12612000209897Professor Charlie Xua104
Not yet recruiting
Not Applicable
To study the effect of â??Dashemani Kandughna Gelâ?? local application in the management of Dandruff ( itching over scalp, Flakes on scalp etc)Health Condition 1: L00-L99- Diseases of the skin and subcutaneous tissueCTRI/2020/12/030010Dr Nilima Sanjay Dharkar
Not yet recruiting
Phase 2
A Pharmacokinetic study Of Basti in HumansCTRI/2022/09/045276Dr Kusuma H